Univariate factors associated with longitudinal QOL (time × factor interaction)
| Variable . | β (95% CI) . | Standard error . | P value . |
|---|---|---|---|
| Age (y) | −0.03 (−0.09 to 0.04) | 0.03 | .435 |
| Female sex | 0.40 (−10.8 to 3.82) | 3.73 | .349 |
| Married/with a partner | −0.06 (−1.79 to 1.66) | 0.88 | .944 |
| College educated | 0.01 (−1.48 to 1.49) | 0.76 | .992 |
| Income ≥$100 000 | −0.74 (−2.35 to 0.87) | 0.82 | .369 |
| White race | −0.85 (−3.10 to 1.40) | 1.15 | .460 |
| Bridging therapy use | 0.67 (−0.87 to 2.20) | 0.78 | .395 |
| ECOG performance status | 1.24 (0.04-2.43) | 0.61 | .042 |
| Diagnosis of lymphoma/leukemia | −0.93 (−2.48 to 0.62) | 0.79 | .238 |
| Months since diagnosis | 0.00 (−0.01 to 0.02) | 0.01 | .602 |
| CAR-T Product | |||
| BCMA CAR-T (ref) | Ref | Ref | Ref |
| Tisa-cel | 0.56 (−8.64 to 9.76) | 4.70 | .905 |
| Axi-cel or Brexu-cel | 5.84 (−4.71 to 16.4) | 5.39 | .278 |
| Liso-cel | 7.57 (−3.58 to 18.7) | 5.69 | .183 |
| CRS | 0.06 (−1.65 to 1.76) | 0.87 | .948 |
| Immune effector cell-associated neurologic toxicity syndrome | 0.97 (−0.62 to 2.57) | 0.81 | .231 |
| Receipt of tocilizumab | 1.54 (0.06-3.02) | 0.76 | .042 |
| Receipt of corticosteroids | 2.05 (0.60-3.51) | 0.74 | .006 |
| Variable . | β (95% CI) . | Standard error . | P value . |
|---|---|---|---|
| Age (y) | −0.03 (−0.09 to 0.04) | 0.03 | .435 |
| Female sex | 0.40 (−10.8 to 3.82) | 3.73 | .349 |
| Married/with a partner | −0.06 (−1.79 to 1.66) | 0.88 | .944 |
| College educated | 0.01 (−1.48 to 1.49) | 0.76 | .992 |
| Income ≥$100 000 | −0.74 (−2.35 to 0.87) | 0.82 | .369 |
| White race | −0.85 (−3.10 to 1.40) | 1.15 | .460 |
| Bridging therapy use | 0.67 (−0.87 to 2.20) | 0.78 | .395 |
| ECOG performance status | 1.24 (0.04-2.43) | 0.61 | .042 |
| Diagnosis of lymphoma/leukemia | −0.93 (−2.48 to 0.62) | 0.79 | .238 |
| Months since diagnosis | 0.00 (−0.01 to 0.02) | 0.01 | .602 |
| CAR-T Product | |||
| BCMA CAR-T (ref) | Ref | Ref | Ref |
| Tisa-cel | 0.56 (−8.64 to 9.76) | 4.70 | .905 |
| Axi-cel or Brexu-cel | 5.84 (−4.71 to 16.4) | 5.39 | .278 |
| Liso-cel | 7.57 (−3.58 to 18.7) | 5.69 | .183 |
| CRS | 0.06 (−1.65 to 1.76) | 0.87 | .948 |
| Immune effector cell-associated neurologic toxicity syndrome | 0.97 (−0.62 to 2.57) | 0.81 | .231 |
| Receipt of tocilizumab | 1.54 (0.06-3.02) | 0.76 | .042 |
| Receipt of corticosteroids | 2.05 (0.60-3.51) | 0.74 | .006 |
β-weights indicate differences in FACT-G QOL score based on each univariate predictor. Bolded values are for those with a P value < 0.05.